Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis
OBJECTIVE: To investigate if the addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis (MDR-TB) could improve patient outcomes.
METHODS: A prospective, randomized, controlled study was conducted in patients with MDR-TB. Treatment was for 18 months. Patients in the experimental group received bedaquiline and clofazimine in addition to their regular treatment regimen whereas patients in the control group did not.
RESULTS: 68 patients with MDR-TB were randomised to treatment, 34 to each group. At the end of treatment, cure rates were statistically significantly greater for the experimental group compared with the control group (82% vs. 56%). There was no difference between groups in the number of severe adverse events (3[9%]) in both groups and none were skin-related.
CONCLUSIONS: The addition of bedaquiline and clofazimine to the treatment regimen significantly improves outcomes for patients with MDR-TB. Clinicians should be aware of the clinical benefits of this addition but be mindful of contraindications and adverse effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
The Journal of international medical research - 51(2023), 1 vom: 31. Jan., Seite 3000605221148416 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yao, Ge [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
78846I289Y |
|---|
| Anmerkungen: |
Date Completed 02.02.2023 Date Revised 04.02.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1177/03000605221148416 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352296593 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352296593 | ||
| 003 | DE-627 | ||
| 005 | 20231226053405.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/03000605221148416 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM352296593 | ||
| 035 | |a (NLM)36719280 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yao, Ge |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Improved outcomes following addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.02.2023 | ||
| 500 | |a Date Revised 04.02.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To investigate if the addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis (MDR-TB) could improve patient outcomes | ||
| 520 | |a METHODS: A prospective, randomized, controlled study was conducted in patients with MDR-TB. Treatment was for 18 months. Patients in the experimental group received bedaquiline and clofazimine in addition to their regular treatment regimen whereas patients in the control group did not | ||
| 520 | |a RESULTS: 68 patients with MDR-TB were randomised to treatment, 34 to each group. At the end of treatment, cure rates were statistically significantly greater for the experimental group compared with the control group (82% vs. 56%). There was no difference between groups in the number of severe adverse events (3[9%]) in both groups and none were skin-related | ||
| 520 | |a CONCLUSIONS: The addition of bedaquiline and clofazimine to the treatment regimen significantly improves outcomes for patients with MDR-TB. Clinicians should be aware of the clinical benefits of this addition but be mindful of contraindications and adverse effects | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bedaquiline | |
| 650 | 4 | |a clofazimine | |
| 650 | 4 | |a multidrug-resistant tuberculosis | |
| 650 | 7 | |a bedaquiline |2 NLM | |
| 650 | 7 | |a 78846I289Y |2 NLM | |
| 650 | 7 | |a Clofazimine |2 NLM | |
| 650 | 7 | |a D959AE5USF |2 NLM | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 700 | 1 | |a Zhu, Muxin |e verfasserin |4 aut | |
| 700 | 1 | |a Nie, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Nanshan |e verfasserin |4 aut | |
| 700 | 1 | |a Tu, Shengjin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Fan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Xi |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Hua |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of international medical research |d 1973 |g 51(2023), 1 vom: 31. Jan., Seite 3000605221148416 |w (DE-627)NLM000148504 |x 1473-2300 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2023 |g number:1 |g day:31 |g month:01 |g pages:3000605221148416 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/03000605221148416 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2023 |e 1 |b 31 |c 01 |h 3000605221148416 | ||